AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05804825 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Simple forewarning message
Description: Participants will be presented with a simple forewarning message.
Study NCT06311266 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Robotic endoscopic neurosurgical intervention
Description: Robotic guidance device for intraoperative trajectory alignment in endoscopic neurosurgical procedures
Study NCT04775459 — intervention group
Intervention type: DRUG
Intervention: Surfactant administration since 2021
Description: Surfactant is administrated if Fi02 >30% OR if score LUS >8/18 among the literature
Study NCT06623890 — intervention group
Intervention type: DRUG
Intervention: Omaveloxolone
Description: Administered as specified in the treatment arm.
Study NCT06622590 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QIV
Description: Quadrivalent Influenza Virus Split Vaccine containing H1N1, H3N2, Bv, By antigens of 0.5ml for each dose
Study NCT05067023 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI scan
Description: All participants will undergo 1 DCE-MRI scan.
Study NCT06622590 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: QIV control
Description: Quadrivalent Influenza Virus Split Vaccine containing each type of antigens of 0.5ml for each dose
Study NCT04962139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ON101 Cream
Description: Active ingredients: Extracts of Plectranthus amboinicus and Centella Asiatica
Study NCT04962139 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Cream
Description: ON101 Cream Placebo
Study NCT06162702 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation
Description: Fecal microbiota transplantation (FMT) achieves the purpose of treating intestinal and extra-intestinal diseases by transplanting the functional microbes in the feces of healthy people into the patient's intestine through the upper or lower alimentary tract routes to rebuild the patient's intestinal microbiota.
Study NCT02911961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: 1 gram acetaminophen 4 times a day with at least 6 hour intervals between doses for the 3 days prior to the embolization procedure.
Study NCT05100862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Zanubrutinib will be administered orally as two 80-milligram (mg) capsules twice a day (160 mg twice a day) or four 80-mg capsules once a day (320 mg once a day) continuously in repeated 28-day cycles.
Study NCT05100862 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab will be administered intravenously at a dose of 375 mg/meter squared on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. Each cycle is 28 days in length.
Study NCT05100862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be administered intravenously at a dose of 375 mg/meter squared on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. Each cycle is 28 days in length.
Study NCT05100862 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Lenalidomide will be administered orally as 20-mg capsules (10 mg if creatinine clearance ≥ 30 mL/min but \< 60 mL/min) once a day on Days 1 to 21 of each 28-day cycle for a total of 12 cycles.
Study NCT05100862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab will be administered at a dose of 1000 mg on Cycle 1 Days 1, 8, 15 and then on Cycles 2 to 6 Day 1.
Study NCT05459350 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Safe Discharge Classification
Description: Safe Discharge Classification
Study NCT06624878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esketamine
Description: 0.2 mg/kg esketamine infused intravenously after induction of general anesthesia.
Study NCT06624878 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: a placebo (an equivalent volume of normal saline) infused intravenously after induction of general anesthesia.
Study NCT06363591 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Wise vs wide
Description: Wise vs wide excisions for thin melanoma
Study NCT06363591 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wise vs wide
Description: Wise vs wide excisions for thin melanoma
Study NCT05427487 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IVX037
Description: Bioselected oncolytic RNA virus
Study NCT06133530 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Human milk oligosaccharides
Description: Prebiotic
Study NCT06133530 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltose
Description: Control
Study NCT05522023 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: group treated with aromatic solution
Description: The aromatic solution applied in the experimental group will be obtained by mixing lavender oil and ginger oil into cold drinking water. For this, lavender and ginger oil approved by the Ministry of Agriculture will be used. 3 drops of lavender oil and 3 drops of ginger oil will be mixed into each 100 ml of drinking water, and it will be applied by spraying 4 times in the oral cavity and throat by shaking to ensure homogeneous distribution before each use. The aromatic solution to be applied in the study will be applied with spray bottles with mouth caps and caps that will be specially provided for each patient.
Study NCT05522023 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: group treated with drinking water
Description: In the placebo group, drinking water will be sprayed 4 times in the oral cavity and throat of the patients after the surgery. The aromatic solution to be applied in the study will be applied with spray bottles with mouth caps and caps that will be specially provided for each patient.
Study NCT05427487 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: An immune checkpoint inhibitor
Study NCT05273554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given by IV
Study NCT05022615 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Topcon Camera
Description: Standard 7 field imaging
Study NCT05273554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenvatinib
Description: Given by PO
Study NCT04271306 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfs25-IMX313 (10ug)/Matrix-M (50ug)
Description: 3 doses of Pfs25-IMX313/Matrix-M at Pfs25-IMX313(10µg)/Matrix-M (50µg)
Study NCT04271306 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfs25-IMX313 (50ug)/Matrix-M (50ug)
Description: 3 doses of Pfs25-IMX313/Matrix-M at Pfs25-IMX313(50µg)/ Matrix-M (50µg)
Study NCT04271306 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfs25-IMX313 (50ug)/Matrix-M (50ug) & Pfs25-IMX313 (10ug)/Matrix-M (50ug)
Description: 2 doses of Pfs25-IMX313/Matrix-M at Pfs25-IMX313(50µg)/ Matrix-M (50µg) followed by one at Pfs25-IMX313(10µg)/Matrix-M (50µg)
Study NCT05727020 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Breath test
Description: Patients must be fasted for a minimum of six hours prior to sample collection. For patients undergoing surgery or a procedure (e.g. endoscopy), breath samples must be obtained pre-operatively / prior to the administration of sedation, anaesthetic or other pharmacological agents.
Study NCT05727020 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Collection of matched samples of breath, biofluids and pancreatic tissue
Description: In accordance with routine clinical practices, patients will be fasted for a minimum of six hours prior to surgery. Exhaled breath, saliva, blood and urine will be collected immediately prior to surgery (before induction of general anaesthesia). Pancreatic tissue samples and duodenal aspirate which will be collected upon resection of the pancreatic specimen.
Study NCT05022615 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Optos Camera
Description: Ultrawide field imaging
Study NCT05022615 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Clarus Camera
Description: Ultrawide field imaging
Study NCT05480540 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Serious game
Description: According to the curriculum, as of the third week, a serious game-based web application on Sterile Dressing and Surgical Instrument Preparation Training, which is prepared in accordance with the formal education curriculum and prepared as a support for formal education, will be downloaded to the mobile phones of the students in the intervention group as of the third week. Students would be informed that they could use the application for two weeks whenever they wanted and as much as they wanted.
Study NCT05480540 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Serious game
Description: According to the curriculum, as of the third week, a serious game-based web application on Sterile Dressing and Surgical Instrument Preparation Training, which is prepared in accordance with the formal education curriculum and prepared as a support for formal education, will be downloaded to the mobile phones of the students in the intervention group as of the third week. Students would be informed that they could use the application for two weeks whenever they wanted and as much as they wanted.
Study NCT04348747 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-HER2/HER3 Dendritic Cell Vaccine
Description: Given ID
Study NCT04348747 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT05249933 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Deyou; Beijing Tide Pharmaceutical Co, China, containing 20,000 iu pronase granules combined with 1 g NaHCO3 to maintain the intragastric PH at 6-8
Description: Drink Deyo with 200ml warm water 25 minutes before swallowing the capsule to remove mucus in the stomach.
Study NCT05249933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deyou; Beijing Tide Pharmaceutical Co, China, containing 20,000 iu pronase granules combined with 1 g NaHCO3 to maintain the intragastric PH at 6-8
Description: Drink Deyo with 200ml warm water 25 minutes before swallowing the capsule to remove mucus in the stomach.
Study NCT04717336 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SODIUM CHLORIDE
Description: It is well established that increased dietary sodium can predispose to an increase in blood pressure; particularly in salt-sensitive individuals. Seeking to test the hypothesis that changes in dietary sodium intake are sufficient to influence the composition of the gut microbiome in association with sodium-induced changes in vascular function, epigenome, transcriptome and blood pressure in African Americans.
Study NCT05677451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOU064 (blinded)
Description: LOU064 (blinded) active treatment
Study NCT05677451 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching active drug
Study NCT06693687 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Metastatic Cancer
Description: Participants will be asked to to take part in a research study because you have metastatic cancer (meaning that your cancer has spread to other parts of the body) and will be starting systemic therapy.
Study NCT06777719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eight Treg
Description: The experimental drug Eight Treg is given to patients with a peripheral IV infusion the day before the graft (cf section 5.1.5. Infusion of the experimental drug of this protocol) in addition to the maintenance protocol combining corticosteroids, tacrolimus and MPA which are classically pre-scribed in kidney graft patients from a living donor at the Nantes CHU.
Study NCT06328777 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CABA-201
Description: Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide
Study NCT05410145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D3S-001
Description: Oral
Study NCT06044285 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low UP (meals provided)
Description: This study incorporates within- and between-subject comparisons. All participants complete a series of three in-lab visits with remote data collection:~Visit 1 and the following week comprise the baseline assessment period.~Visit 2 and the following week comprise the dietary intervention period. Food is provided by the study team for 7 days in accordance with a low UP diet.~Visit 3 assesses post-dietary intervention outcomes. All participants will complete remote assessments at 1 month and 3 month follow-up.
Study NCT05410145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous
Study NCT05410145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Intravenous
Study NCT05410145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Intravenous
Study NCT06044285 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low UP (self-guided)
Description: Visit 1 and the following week comprise the baseline assessment period.~Visit 2 and the following week comprise the dietary intervention period. Participants are asked to eat a low UP diet according to study provided nutritional guidance.~Visit 3 assesses post-dietary intervention outcomes. All participants will complete remote assessments at 1 month and 3 month follow-up.
Study NCT05410145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Intravenous
Study NCT05410145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Intravenous
Study NCT06044285 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: Visit 1 and the following week comprise the baseline assessment period.~Visit 2 and the following week comprise the dietary intervention period. Participants are asked to eat as they normally do.~Visit 3 assesses post-dietary intervention outcomes. All participants will complete remote assessments at 1 month and 3 month follow-up.
Study NCT06624969 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual reality
Description: Virtual reality program to reduce pain in orthopedic fractures
Study NCT06694454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacytidine
Description: Aerosolized azacytidine (AZA) via nebulizer on 3 consecutive days during the first week of every cycle (1 cycle=21 days), for a maximum (total) of 3 cycles.~Azacytidine will be given at escalating doses in phase 1, and at the established RP2D in phase 2.
Study NCT06694454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Carboplatin (intravenous/IV), area under the serum drug concentration-time curve (AUC)=5-6 mg/mL/min based on cancer histology administered on day 4 of every cycle (1 cycle=21 days), for a maximum (total) of 3 cycles.
Study NCT06694454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Paclitaxel (IV), 200 mg/m\^2, is administered on day 4 of every cycle (1 cycle=21 days), for a maximum (total) of 3 cycles.
Study NCT04717336 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo capsules
Study NCT06694454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: durvalumab
Description: Durvalumab (IV) administered as a flat dose of 1500 mg on day 4 of every cycle (1 cycle=21 days), for a maximum (total) of 3 cycles.
Study NCT06694454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Cisplatin (IV), 75 mg/m\^2, administered on day 4 of every cycle (1 cycle=21 days), for a maximum (total) of 3 cycles.
Study NCT06278506 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ablation
Description: Microwave ablation, Radiofrequency ablation, Cryo ablation
Study NCT05258175 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KT
Description: Kinesio tapping will be applied in three session and it will be changed on every fifth day in total 15 days.
Study NCT05258175 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized physiotherapy protocol
Description: 3 sets with five repetitions per day for total of 15 days.
Study NCT05258175 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standardized physiotherapy protocol
Description: 3 sets with five repetitions per day for total of 15 days.
Study NCT05531084 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgeon-Modified fenestrated stent grafts using Cook Zenith Platform (Zfen, TX2, Alpha Thoracic Endovascular Graft and Zenith Flex)
Description: Depending on the location of the aneurysm, patients with failed EVAR and complex aortic pathology requiring fenestrated and branched endovascular repair will be treated with physician-modified Cook Zenith devices (Zenith Flex, Zenith Fenestrated stent graft (Zfen), Cook Alpha Thoracic Endovascular Graft, Cook dissection TX2), and their associated commercially approved ancillary components.
Study NCT06278506 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Partial or total nefrectomy
Study NCT06061276 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bTAE-HAIC
Description: bTAE procedure was a 2.8-F microcatheter was superselectively inserted into the tumor feeding artery using the coaxial technique. Then blank microspheres were used according to the tumor blood supply vessels (40-120um, 100-300um, 300-500um, 500-700um). The microcatheter was reserved at the proper/left/right hepatic artery according tumor location. After the patient returned to the ward, the following FOLFOX-based regime was intra-arterially administered through the microcatheter. The FOLFOX regimen was administered via the hepatic artery as follows: 85 or 135 mg/m2 oxaliplatin from hour 0 to 2 on day 1, and 400 mg/m2 leucovorin from hour 2 to 4 on day 1, and 400 mg/m2 fluorouracil bolus at hour 5 on the day 1; and 2400 mg/m2 fluorouracil over 46 h on days 1 and 2.
Study NCT06061276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 12 mg (or 8 mg) once daily (QD) oral dosing.
Study NCT06061276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: 200mg intravenously every 2 weeks
Study NCT04867720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: - Oral intake, BID - After first dose 1mg(total 2mg daily), check the blood concentration of everolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 3\~8mg/mL.
Study NCT05665101 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coil embolization of aneurysm sac
Description: Patients are treated with standard EVAR with additional coiling of the aneurysm sac. The distinct type of coils used is not predefined.
Study NCT05807087 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional osteotomy
Description: The nasal skeleton was accessed using a closed approach or an open approach is done via a transcolumellar and infracartilaginous incision. Osteotomy was made using osteotomes.
Study NCT05807087 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Piezosurgery osteotomy
Description: full exposure of the nasal bony pyramid is needed.
Study NCT06298617 — intervention group
Intervention type: PROCEDURE
Intervention: Diagnostic laparoscopy
Description: All women will undergo exploratory laparoscopy under general anesthesia
Study NCT06298617 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Full Blood Count (FBC)
Description: Blood samples withdrawn from patients on EDITA tubes and gone through full blood count and differential leucocytic count
Study NCT04852705 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 Vaccine (Vero Cells), Inactivated
Description: 2 doses of SARS-CoV-2 Vaccine (Vero Cells), Inactivated should be administered as an intramuscular injection into the lateral deltoid of the upper arm with a 28-day interval.
Study NCT04852705 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 doses of Placebo should be administered as an intramuscular injection into the lateral deltoid of the upper arm with a 28-day interval.
Study NCT05705375 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Waterpipe size
Description: Participants will have 3 lab visits where they are allocated (random order) to smoke a small waterpipe in one visit, smoke a medium waterpipe in a second visit and smoke a large waterpipe in a third visit.
Study NCT04871412 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3 Drops
Description: 1,000 - 10,000 units daily based on serum levels for the duration of the study
Study NCT04871412 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coriolus Versicolor
Description: 1.5g twice daily for the duration of the study
Study NCT04871412 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Trident SAP 66:33 Lemon
Description: 3g once daily for the duration of the study
Study NCT04871412 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic Pro12
Description: 12 billion colony forming units daily during the peri-operative period (approximately 1 month pre and post-surgery)
Study NCT04871412 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Provitalix Pure Whey Protein
Description: 1 scoop (22g) once daily during the peri-operative period (approximately 1 month pre and post-surgery) and during any adjuvant chemotherapy and radiation treatments